

# CURRICULUM VITAE

**ORESTIS A. PANAGIOTOU, M.D., Ph.D.**

PERSONAL INFORMATION .....	1
EDUCATION .....	1
ACADEMIC APPOINTMENTS .....	1
OTHER APPOINTMENTS.....	1
PROFESSIONAL LICENSES AND CERTIFICATIONS.....	2
HONORS AND AWARDS .....	2
MEMBERSHIP IN SOCIETIES .....	2
NATIONAL OR INTERNATIONAL SERVICE .....	3
Grant Application Review Boards .....	3
Editorial Responsibilities .....	3
Journal Manuscript Reviewer (non-exhaustive list) .....	3
PUBLICATIONS IN PEER-REVIEWED JOURNALS .....	3
PEER-REVIEWED REPORTS, WHITE PAPERS & TECHNOLOGY ASSESSMENTS .....	11
OTHER PUBLICATIONS.....	12
BOOKS AND BOOK CHAPTERS .....	13
SCHOLARLY WORK PUBLISHED IN OTHER MEDIA.....	14
INVITED PRESENTATIONS & TALKS.....	14
National.....	14
International .....	16
OTHER PRESENTATIONS .....	16
National.....	16
International .....	17
GRANTS .....	18
Current Grants .....	18
Completed Grants.....	21
UNIVERSITY TEACHING AND MENTORING ROLES.....	23

## CURRICULUM VITAE

**ORESTIS A. PANAGIOTOU, M.D., Ph.D.**

### PERSONAL INFORMATION

Address: 121 S. Main St., Providence, RI 02906

Phone: 401-863-3894

Fax: 401-863-3489

E-mail: [orestis\\_panagiotou@brown.edu](mailto:orestis_panagiotou@brown.edu)

### EDUCATION

- 2009      **M.D.**  
University of Ioannina School of Medicine, Ioannina, Greece  
GPA: 3.69 / 4.00
- 2015      **Ph.D., Epidemiology**  
University of Ioannina School of Medicine, Ioannina, Greece
- 2016      **Postdoctoral Fellow, Biostatistics**  
Division of Cancer Epidemiology & Genetics, National Cancer Institute, National  
Institutes of Health, Rockville, MD

### ACADEMIC APPOINTMENTS

- 2009 -      Research Associate, Department of Hygiene and Epidemiology, University of  
2013      Ioannina School of Medicine, Ioannina, Greece
- 2016 -      Assistant Professor (Research), Department of Health Services, Policy &  
Practice, Brown University School of Public Health, Providence, RI

### OTHER APPOINTMENTS

- 2016 -      Investigator, Center for Gerontology & Healthcare Research, Brown University  
School of Public Health, Providence, RI
- 2016 -      Affiliated Faculty, Center for Evidence Synthesis in Health, Brown University  
School of Public Health, Providence, RI
- 2016 -      Investigator, Evidence-based Practice Center, Brown University School of  
Public Health, Providence, RI

2020 - Member, Cancer Center at Brown University, Providence, RI

## PROFESSIONAL LICENSES AND CERTIFICATIONS

2009 Medical Practice License, Prefecture of Epirus, Ioannina, Greece

2012 General Medical Council, UK.

## HONORS AND AWARDS

2013 Best Reviewer Award, *Pharmacoepidemiology & Drug Safety*

2014 AACR-Millennium Scholar-In-Training Award, American Association for Cancer Research. AACR Annual Meeting 2016. San Diego, CA

2015 Fellowship Achievement Award, Division of Cancer Epidemiology & Genetics, National Cancer Institute

2015 2016 Kuan-Teh Jeang Scholar, National Institutes of Health Virology Interest Group

2016 Fellows Award for Research Excellence (FARE), Office of Intramural Training & Education, NIH Intramural Research Program

2016 AACR-Dr. Richard L. Welsh Scholar-In-Training Award, American Association for Cancer Research. AACR Annual Meeting 2016. New Orleans, LA

2016 Outstanding Research Paper Award, Division of Cancer Epidemiology & Genetics, National Cancer Institute

2019 Top Reviewer in 2018, *Annals of Internal Medicine*

2020 Top Reviewer in 2019, *Annals of Internal Medicine*

## MEMBERSHIP IN SOCIETIES

2018 - Cochrane Collaboration, Member

2015 - American Statistical Association (ASA), Member

2014 - American Society of Clinical Oncology (ASCO), Member

2013 - American Association for Cancer Research (AACR), Associate Member

2013 - Society of Epidemiologic Research (SER), Member

2013 - American College of Epidemiology (ACE), Member

## NATIONAL OR INTERNATIONAL SERVICE

### Grant Application Review Boards

- 06/2020 Cancer, Heart, and Sleep Epidemiology Panel A (CHSA) Study Section, Center for Scientific Review, National Institutes of Health (*Ad hoc reviewer*)
- 08/2020 Special Emphasis Panel ZHS1 HSR-D (02) “Evaluating Health System and Healthcare Professional Responsiveness to COVID-19”, Agency for Healthcare Research and Quality
- 10/2020 Cancer, Heart, and Sleep Epidemiology Panel A (CHSA) Study Section, Center for Scientific Review, National Institutes of Health (*Ad hoc reviewer*)

### Expert Reviewer on White Papers

- 12/2020 U.S. National Cancer Institute Tobacco Control Monograph 23 “*Tobacco Use in the Context of Oncology Care and Survivorship*”

### Editorial Responsibilities

- 2021 – *BMC Medical Research Methodology* (Editorial Board Member)
- 2021 – *Systematic Reviews*

### Journal Manuscript Reviewer (non-exhaustive list)

*Annals of Internal Medicine, American Journal of Epidemiology, BMJ, Bioinformatics, BMC Cardiovascular Disorders, BMC Genomics, BMC Medical Genetics, BMC Medical Research Methodology, British Journal of Cancer, British Journal of Dermatology, Cancer Epidemiology, Biomarkers & Prevention (CEBP), Epidemiology, European Journal of Clinical Investigation (EJCI), Genetics in Medicine, JACC: CardioOncology, JAMA, JAMA Internal Medicine, Journal of the National Cancer Institute (JNCI), Nature Communications, Pharmacoepidemiology & Drug Safety, PLoS Computational Biology, Scientific Reports.*

## PUBLICATIONS IN PEER-REVIEWED JOURNALS

*Equal contributions are delineated with \*. Mentees are delineated with underscore.*

1. **Panagiotou OA**, Evangelou E, Ioannidis JP. Genome-wide significant associations for variants with minor allele frequency of 5% or less– an overview: A HuGE review. *American Journal of Epidemiology*. 2010;172:869-89. Epub 2010 Sep 28.
2. **Panagiotou OA**, Contopoulos-Ioannidis DG, Papanikolaou PN, Ntzani EE, Ioannidis JP.

- Different black box warning labeling for same-class drugs. *Journal of General Internal Medicine*. 2011;26:603-10. Epub 2011 Feb 1. Accompanied by editorial in the same issue by S.B. Dusetzina and G.C. Alexander.
3. Ioannidis JP, **Panagiotou OA**. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. *JAMA*. 2011;305:2200-10. Accompanied by editorial in the same issue by P.M. Bossuyt.
  4. **Panagiotou OA**, Ioannidis JP; for the Genome-Wide Significance Project. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. *International Journal of Epidemiology*. 2012;41:273-86. Epub 2011 Dec 5. Accompanied by editorial in the same issue by J. Wakefield.
  5. **Panagiotou OA**, Ioannidis JP. Primary study authors of significant studies are more likely to believe that a strong association exists in a heterogeneous meta-analysis compared with methodologists. *Journal of Clinical Epidemiology*. 2012;65:740-7. Epub 2012 Apr 25.
  6. Doufas AG, **Panagiotou OA**, Ioannidis JP. Concordance of sleep and pain outcomes of diverse interventions: an umbrella review. *PLoS ONE*. 2012;7:e40891. Epub 2012 Jul 17.
  7. Yioti GG, **Panagiotou OA**, Vartholomatos GA, Kolaitis NI, Pappa CN, Evangelou E, Stefaniotou MI. Genetic polymorphisms associated with retinal venous occlusion: a Greek case-control study and meta-analysis. *Ophthalmic Genetics*. 2013;34:130-9. Epub 2013 Jan 4.
  8. Stefanaki I, **Panagiotou OA\***, Kodela E\*, Gogas H, Kypraiou KP, Chatzinasiou F, Nikolaou V, Plaka M, Kalfa I, Antoniou C, Ioannidis JP, Evangelou E, Stratigos AJ. Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. *PLoS ONE*. 2013;8:e55712. Epub 2013 Feb 5.
  9. **Panagiotou OA**, Contopoulos-Ioannidis DG, Ioannidis JP. Comparative effect sizes in randomized trials from less developed versus more developed countries. *BMJ*. 2013;346:f707.
  10. **Panagiotou OA**, Willer C, Hirschhorn JN, Ioannidis JP. The power of meta-analysis in genome-wide association studies. *Annual Review of Genomics and Human Genetics*. 2013;14:441-465. Epub 2013 May 24.
  11. Tsilidis KK\*, **Panagiotou OA\***, Sena ES, Aretouli E, Evangelou E, Howells DW, Al-Shahi Salman R, Macleod MR, Ioannidis JP. Evaluation of excess significance bias in animal studies of neurological diseases. *PLoS Biology*. 2013;7:e1001609. Epub 2013 Jul 16. Accompanied by editorial in the same issue by J.M. Chase.
  12. Lathyris D, **Panagiotou OA**, Baltogianni M, Ioannidis JP, Contopoulos-Ioannidis DC. Safety of medical interventions in children vs. adults. *Pediatrics*. 2014;133:e666-e673. Epub 2014 Feb 24.
  13. Gu F, Wacholder S, Kovalchik SA, **Panagiotou OA**, Reyes-Guzman C, Freedman ND, De Matteis S, Consonni D, Bertazzi PA, Bergen AW, Landi MT, Caporaso NE. Time to smoke first morning cigarette and lung cancer in a case-control study. *Journal of the National*

- Cancer Institute**. 2014;106:dju118.
14. Flegal KM, **Panagiotou OA**, Graubard BI. Estimating population attributable fractions to quantify the health burdens of obesity. **Annals of Epidemiology**. 2015;25:201-7. Epub 2014 Nov 13.
  15. Belbasis L, **Panagiotou OA**, Dosis V, Evangelou E. A systematic appraisal of field synopses in genetic epidemiology: a HuGE review. **American Journal of Epidemiology**. 2015;181:1-16. Epub 2014 Dec 11.
  16. **Panagiotou OA**, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Gurrea AB, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN; The PRACTICAL Consortium, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK. Genome-wide pleiotropy scan for prostate cancer. **European Urology**. 2015;67:649-657. Epub 2014 Sep 29. Accompanied by editorial in the same issue by A. Cox.
  17. Guertin KA, Gu F, Wacholder S, Freedman ND, **Panagiotou OA**, Reyes-Guzman C, Caporaso NE. Time to first morning cigarette and risk of chronic obstructive pulmonary disease: smokers in the PLCO cancer screening trial. **PLoS ONE**. 2015;10:e0125973.
  18. Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, **Panagiotou OA**, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Caminada de Toledo SR, Petrilli AS, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Fernanda Amary M, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. **Cancer Discovery**. 2015;5:920-31. Epub 2015 Jun 17.
  19. Sampson JN, Wheeler WA\*, Yeager M\*, **Panagiotou O\***, Wang Z\*, Berndt SI\*, Lan Q\*, Abnet CC\*, Amundadottir LT\*, Figueroa JD\*, Landi MT\*, Mirabello L\*, Savage SA\*, Taylor PR\*, De Vivo I\*, McGlynn KA\*, Purdue MP\*, Rajaraman P\*, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W,

Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kaminen A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Krickler A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh JJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupert M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. *Journal of the National Cancer Institute*. 2015;107(12):d1v279

20. **Panagiotou OA**, Befano B, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S; on behalf of the Costa Rica HPV

- Vaccine Trial (CVT) Group. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. *BMJ*. 2015;351:h4358. Accompanied by editorial in the same issue by K. Canfell.
21. Harari A, Chen Z, Rodríguez AC, Hildesheim A, Porras P, Herrero R, Wacholder S, **Panagiotou OA**, Befano B, Burk RD, Schiffman M; for the Costa Rica Vaccine Trial (CVT) Group. Cross-protection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections. *Journal of Infectious Diseases*. 2016;213:939-47. Epub 2015 Oct 30.
  22. Li Y, **Panagiotou OA**, Black A, Liao D, Wacholder S. Multivariate piecewise exponential survival modeling. *Biometrics*. 2016;72:546-53. Epub 2015 Nov 19.
  23. Contopoulos-Ioannidis DG, Tseretopoulou X, Ancker M, Walterspiel JN, **Panagiotou OA**, Maldonado Y, Ioannidis JP. Comparative rates of harms in randomized trials from more-developed versus less- developed countries may be different. *Journal of Clinical Epidemiology*. 2016;78:10-21. Epub 2016 April 5. Accompanied by editorial in the same issue by J.A. Knottnerus and P. Tugwell.
  24. Nelson SM, Anic GM, **Panagiotou OA**, Mondul AM, Männistö S, Weinstein SJ, Albanes D. Metabolomics analysis of baseline serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. *International Journal of Epidemiology*. 2016;45(5):1458-1468. Epub 2016 Aug 14.
  25. Doufas AG, **Panagiotou OA**, Panousis P, Shucheng SW, Ioannidis JP. Insomnia from drug treatments: evidence from meta-analyses of randomized trials and concordance with package insert prescribing information. *Mayo Clinic Proceedings*. 2017;92(1):72-87. Epub 2016 Nov 11.
  26. Huang J\*, **Panagiotou OA\***, Anic GM, Mondul AM, Liao LM, Derkach A, Stolzenberg-Solomon R, Weinstein SJ, Albanes D. Metabolomic profiling of serum retinol in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. *Scientific Reports*. 2017;7(1):10601. doi: 10.1038/s41598-017-09698-w.
  27. Schuit E, **Panagiotou OA**, Munafò MR, Bennett DA, Bergen AW, David SP. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. *Cochrane Database of Systematic Reviews*. 2017;9:CD011823. doi: 10.1002/14651858.CD011823.pub2.
  28. Koster R, **Panagiotou OA**, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-García A, Lecanda F, Serra M, Hattinger C, Picci P, Scotlandi K, Thomas DM, Ballinger ML, Gorlick R, Barkauskas DA, Spector LG, Tucker M, Belynda DH, Yeager M, Hoover RN, Wacholder S, Chanock SJ, Savage SA, Mirabello L. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. *International Journal of Cancer*. 2017;142(8):1594-1601.
  29. Trivedi AN, Leyva B, Lee Y, **Panagiotou OA**, Dahabreh IJ. Elimination of cost sharing for screening mammography in Medicare Advantage plans. *New England Journal of*



- Medicine**. 2018;378(3):262-269
30. Boca SM, **Panagiotou OA**, Rao S, McGarvey P, Madhavan S. The future of evidence synthesis in precision oncology: Between systematic reviews and biocuration. **JCO Precision Oncology**. 2018;2:10.1200/PO.17.00175.
  31. **Panagiotou OA**, Markozannes G, Adam GP, Kowalski R, Gazula A, Di M, Bond DS, Ryder BA, Trikalinos TA. Comparative effectiveness and safety of bariatric procedures in Medicare-eligible patients: a systematic review. **JAMA Surgery**. 2018;153(11):e183326.
  32. **Panagiotou OA**, Bergen AW, David SP. Smoking cessation pharmacotherapy based on genetically-informed biomarkers: what is the evidence? **Nicotine & Tobacco Research**. 2019. 21(9):1289-1293
  33. **Panagiotou OA**, Kumar A, Gutman R, Keohane LM, Rivera-Hernandez M, Rahman M, Gozalo P, Mor V, Trivedi AN. Hospital readmissions in Medicare Advantage and traditional Medicare: a retrospective population-based analysis. **Annals of Internal Medicine**. 2019;171(2):99-106. Epub 2019 Jun 25. Accompanied by editorial in the same issue by P. Huckfeldt and N. Sood.
  34. Kumar A, Rivera-Hernandez M, Karmarkar AM, Chou LN, Kuo YF, Baldwin JA, **Panagiotou OA**, Burke RE, Ottenbacher KJ. Social and health-related factors associated with enrollment in Medicare Advantage plans in older adults. **Journal of the American Geriatric Society**. 2019;68(2):313-320.
  35. Lopez DS, Huang D, Tsilidis KK, Khera M, Williams SB, Urban RJ, **Panagiotou OA**, Kuo YF, Baillargeon J, Farias A, Krause T. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. **Clinical Endocrinology (Oxf)**. 2019;91(6):885-891.
  36. Kosar C, Loomer L, Trivedi AN, **Panagiotou OA**, Rahman M. Assessment of rural-urban differences in post-acute care utilization and outcomes among US older adults. **JAMA Network Open**. 2020;3(1):e1918738
  37. Moore A, Kane E, Wang Z, **Panagiotou OA**, Teras LR, Monnereau A, Wong Doo N, Machiela MJ, Skibola CF, Slager SL, Salles G, Camp NJ, Bracci PM, Nieters A, Vermeulen RCH, Vijai J, Smedby KE, Zhang Y, Vajdic CM, Cozen W, Spinelli JJ, Hjalgrim H, Giles GG, Link BK, Clavel J, Arslan AA, Purdue MP, Tinker LF, Albanes D, Ferri GM, Habermann TM, Adami HO, Becker N, Benavente Y, Bisanzi S, Boffetta P, Brennan P, Brooks-Wilson AR, Canzian F, Conde L, Cox DG, Curtin K, Foretova L, Gapstur SM, Ghesquières H, Glenn M, Glimelius B, Jackson RD, Lan Q, Liebow M, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Morton LM, North KE, Offit K, Padoan M, Patel AV, Piro S, Ravichandran V, Riboli E, de Sanjose S, Severson RK, Southey MC, Staines A, Stewart C, Travis RC, Weiderpass E, Weinstein S, Zheng T, Chanock SJ, Chatterjee N, Rothman N, Birmann BM, Cerhan JR, Berndt SI. Genetic risk scores of adult height and risk of four non-Hodgkin lymphoma subtypes. **Frontiers in On cology**. 2020;9:1539.
  38. Kim D, Makineni R, **Panagiotou OA**, Trivedi NA. Assessment of completeness of hospital readmission rates reported in Medicare Advantage contracts' Healthcare Effectiveness

- Data and Information Set. *JAMA Network Open*. 2020;3(4):e203555
39. **Panagiotou OA**, Hoffman-Hogg L, Hricak H, Khleif SN, Levy MA, Magnus D, Murphy MJ, Patel B, Winn RA, Gatsonis C, Cogle CR. Clinical application of predictive software in the care of cancer patients: a review. *JAMA Oncology*. 2020;6(8):1282-1286
  40. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshov DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, **Panagiotou OA**, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020;395(10241):1907-1918. Accompanied by editorial in the same issue by P.M. Poortmans, V. Guarneri and M.J. Cardoso.
  41. Rivera-Hernandez M, Fabius C, Fashaw S, Downer B, Kumar A, **Panagiotou OA**, Epstein-Lubow G. Quality of post-acute care in skilled nursing facilities that disproportionately serve Hispanics with dementia. *Journal of the American Medical Directors Association*. 2020:S1525-8610(20)30542-9
  42. Rivera DR, Peters S, **Panagiotou OA**, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshov DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL., on behalf of the COVID-19 and Cancer Consortium. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study. *Cancer Discovery*. 2020;10(10):1514-1527.
  43. Kosar C, Loomer L, White E, Thomas KS, **Panagiotou OA**, Rahman M. Association of diagnosis coding with differences in short-term mortality between critical access and non-critical access hospitals. *JAMA*. 2020;324(5):481-487.
  44. Di M, **Panagiotou OA**, Reagan J, Niroula R, Olszewski AJ. Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study. *Leukemia & Lymphoma*. 2020;61(14):3360-3368.
  45. McConeghy KW, White E, **Panagiotou OA**, Santostefano C, Halladay C, Feifer RA, Blackman C, Rudolph JL, Mor V, Gravenstein S. Temperature screening for SARS-CoV-2 in nursing homes: Evidence from two national cohorts. *Journal of the American Geriatrics Society*. 2020;68(12):2716-2720
  46. Murad MH, Fiordalisi C, Pillay J, Wilt TJ, O'Connor E, Kahwati L, Hernandez AV, Rutter

- CM, Chou R, Balk EM, Steele DW, Saldanha IJ, **Panagiotou OA**, Chang S, Gerrity M. Making narrative statements to describe treatment effects. *Journal of General Internal Medicine*. 2021;36(1):196-199.
47. **Panagiotou OA**, Kosar C, White E, Bantis LE, Yang X, Santostefano C, Feifer RA, Blackman C, Rudolph JL, Gravenstein S, Mor V. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. *JAMA Internal Medicine*. 2021;181(4):439-448. Accompanied by editorial in the same issue by MJR Aliberti and TJ Avelino-Silva.
  48. **Panagiotou OA**, Voorhies KR, Keohane LM, Kim D, Adhikari D, Kumar A, Rivera-Hernandez M, Rahman M, Gozalo PL, Gutman R, Mor M, Trivedi AN. Association of Inclusion of Medicare Advantage Patients in Hospitals' Risk Standardized Readmission Rates and Hospital Performance and Penalty Status. *JAMA Network Open*. 2021;4(2):e2037320
  49. **Panagiotou OA**, Keeney T, Ogarek JA, Wulff-Burchfield E, Olszewski AJ, Bélanger E. Prevalence of functional limitations and their associations with systemic cancer therapy among older adults in nursing homes with advanced non-small cell lung cancer. *Journal of Geriatric Oncology*. 2021;S1879-4068(21)00016-3
  50. Kosar CM, White EW, Feifer RA, Blackman C, Gravenstein S, McConeghy K, **Panagiotou OA**, Mor V. Assessment of Trends in Short-Term Mortality Rates among Nursing Home Residents with SARS-CoV-2. *Health Affairs*. 2021;40(4):655-663. Epub 2021 Mar 11.
  51. **Panagiotou OA**, Heller R. Inferential Challenges for Real-world Evidence in the Era of Routinely Collected Health Data: Many Researchers, Many More Hypotheses, a Single Database. *JAMA Oncology*. 2021 Sep 9. doi: 10.1001/jamaoncol.2021.3537 (Viewpoint article)
  52. Lavasidis G, Markozannes G, **Panagiotou OA**, Trikalinos NA, Petridou ET, Voorhies KR, Ntzani EE. Therapeutic interventions for childhood cancer: An umbrella review of randomized evidence. *Crit Rev Oncol Hematol*. 2021; doi: 10.1016/j.critrevonc.2021.103414
  53. Lerner AH, Klein EJ, Hardesty A, **Panagiotou OA**, Misquith C, Farmakiotis D. Comparison of COVID-19 outcomes in organ transplant recipients (OTr) and non-transplant patients: a study protocol for rapid review. *Syst Rev*. 2021;10(1):299.
  54. Di M, Keeney T, Bélanger E, **Panagiotou OA\***, Olszewski AJ\*. Global frailty and therapy for older patients with diffuse large B-cell lymphoma (DLBCL): a population-based study. *JCO Oncology Practice*. 2021. In Press.
  55. Hughes L, King W, Gamarel K, Geronimus A, **Panagiotou OA**, Hughto JMW. Differences in all-cause mortality among transgender and non-transgender people enrolled in private insurance (2011- 2019). *Demography*. In Press
  56. Jaljuli I, Benjamini Y, Shenhav L, **Panagiotou OA**, Heller R. Quantifying replicability and consistency in systematic reviews. Under review. *Also available as arXiv preprint arXiv:1907.06856*

57. Liu MA, Keeney K, Papaila A, Ogarek JA, Khurshid H, Wulff-Burchfield E, Olszewski AJ, Bélanger E, **Panagiotou OA**. Functional status and survival in older nursing home residents with advanced NSCLC: a SEER-Medicare analysis. *JCO Oncology Practice* (Under Review)
58. Elkrief A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, Thomson MA, **Panagiotou OA**, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, Batist G, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J; Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, Khan H, Kim SJ, Klein E, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wise-Draper TM, Mishra S, Grivas P, French B, Warner JL, Wildes TM. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: A COVID-19 and Cancer Consortium Cohort Study. *Lancet Healthy Longevity* (Under Review)
59. Huang AW, Haslberger M, Coulibaly N, Galárraga O, Oganisian A, Belbasis L, **Panagiotou OA**. Multivariable prediction models for health care spending using machine learning: A protocol of a systematic review. *Diagnostic and Prognostic Research* (Under Review)

#### Manuscripts in progress (selected)

60. Voorhies KR, Jaljuli I, Kumar S, Benjamini Y, Schmid, CH, Heller R, **Panagiotou OA**. How often are treatment effects replicated? Empirical insights from randomized clinical trials.
61. Forbes SP, Kumar S, Steingrimsson JA, Adhikari D, Charlesworth CJ, McConnell KJ, Trivedi AN, Trikalinos TA, **Panagiotou OA**. Insurance coverage and low-value care utilization: evidence from an All-Payer Claims Database.
62. Di M, Keeney T, Bélanger E, Olszewski AJ, **Panagiotou OA**. Functional status and therapy for nursing home residents with diffuse large B-cell lymphoma: a population-based study.

#### **PEER-REVIEWED REPORTS, WHITE PAPERS & TECHNOLOGY ASSESSMENTS**

*Agency for Healthcare Research and Quality (AHRQ) Evidence Reports, Comparative Effectiveness Reviews, Technology Assessments and Methods Reports are rigorously peer-reviewed (typically by 5 –15 referees, contrary to just 2 – 4 for Journal publications), and are also subjected to open public review. These products carry substantial weight. They are often commissioned to inform national committees and healthcare coverage decisions. Some of my Journal publications are based on work performed in herein listed reports; any such papers are listed under Publications in Peer-Reviewed Journals. These are not duplicate publications, and are not considered as such neither by AHRQ nor by the journal editors.*

63. **Panagiotou OA**, Markozannes G, Kowalski R, Gazula A, Di M, Bond DS, Ryder BA, Adam GP, Trikalinos TA. *Short- and Long-Term Outcomes after Bariatric Surgery in the Medicare Population*. Technology Assessment Program Project ID: OBST0816 (Prepared

by the Brown Evidence-based Practice Center under Contract No. HHS2902015000051.) Rockville, MD: Agency for Healthcare Research and Quality. September 2018. Available at: <https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/bariatric-surgery/bariatric-surgery-medicare-final-report.pdf>

64. Gerrity M, Fiordalisi C, Pillay J, Wilt TJ, O'Connor E, Kahwati L, Hernandez AV, Rutter CM, Chou R, Balk EM, Steele DW, Saldanha IJ, **Panagiotou OA**, Chang S, Murad MH. *Roadmap for Narratively Describing Effects of Interventions in Systematic Reviews*. Methods White Paper. (Prepared by the Scientific Resource Center under Contract No. 290-2017-00003C.) AHRQ Publication No. 20(21)-EHC018. Rockville, MD: Agency for Healthcare Research and Quality. November 2020. Posted final reports are located on the Effective Health Care Program search page. DOI: 10.23970/AHRQEPWHITEPAPERNARRATIVELY. Available at <https://effectivehealthcare.ahrq.gov/products/roadmap-interventions/white-paper>
65. Zullo AR, Danko KJ, Moyo P, Adam GP, Riester M, Kimmel HJ, **Panagiotou OA**, Beaudoin FL, Carr D, Balk EM. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults. Technical Brief No. 37. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I.) AHRQ Publication No. 21-EHC005. Rockville, MD: Agency for Healthcare Research and Quality. November 2020. DOI: 10.23970/AHRQEPCTB37. Available at <https://effectivehealthcare.ahrq.gov/products/opioids-older-adults/report>
66. Konnyu KJ, Thoma LM, Bhuma MR, Cao W, Adam GP, Mehta S, Aaron RK, Racine-Avila J, **Panagiotou OA**, Pinto D, Balk EM. Prehabilitation and Rehabilitation for Major Joint Replacement. Comparative Effectiveness Review No. 248. (Prepared by the Brown Evidence-based Practice Center under Contract No. 75Q80120D00001.) AHRQ Publication No. 21(22)-EHC033. Rockville, MD: Agency for Healthcare Research and Quality; November 2021. DOI: 10.23970/AHRQEPCCER248. Available at <https://effectivehealthcare.ahrq.gov/products/major-joint-replacement/research>

## OTHER PUBLICATIONS

### Editorials and Commentaries

67. **Panagiotou OA**, Wacholder S. Invited Commentary: How big is that interaction (in my community) – and in which direction? *American Journal of Epidemiology*. 2014;180:1150-8. Epub 2014 Nov 13.
68. **Panagiotou OA**, Trikalinos TA. Commentary: On effect measures, heterogeneity, and the laws of nature. *Epidemiology*. 2015;26(5):710-713 28.

### Correspondence

69. Gu F, Wacholder S, Freedman ND, **Panagiotou OA**, Reyes-Guzman C, Bertazzi PA, Caporaso NE. Time to smoke first morning cigarette and lung cancer in a case-control study – Response. *Journal of the National Cancer Institute*. 2014;106:dju350
70. **Panagiotou OA**. Invited Commentary: How big is that interaction (in my community) – and in which direction? – Reply to Dr. Walter. *American Journal of Epidemiology*. 2016. doi: 10.1093/aje/kww036. Epub April 13, 2016
71. **Panagiotou OA**. Jaljuli I, Heller R. Replicability of treatment effect in study of blood pressure lowering with dementia. *JAMA*. 2020;324(14):1465-1466

### **Book Reviews**

72. **Panagiotou OA**. “Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison. Biondi-Zoccai (ed), Nova Science Publishers, Inc. 2014”. *American Journal of Epidemiology*. 2015 (doi:10.1093/aje/kwu471)
73. **Panagiotou OA**. “Design and Analysis of Clinical Trials for Predictive Medicine. Matsui, Buyse, Simon (eds), Chapman and Hall/CRC 2015”. *Biometrics*. 2017

### **Listed Contributor in Other Publications with Modified Group Authorship (not simply acknowledgment):**

74. The COVID-19 and Cancer Consortium (including **Panagiotou OA**). A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19:CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell*. 2020;38(6):761-766
75. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL; COVID-19 and Cancer Consortium (including **Panagiotou OA**). Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021. doi: 10.1001/jamaoncol.2021.1799.

### **BOOKS AND BOOK CHAPTERS**

76. Marks-Anglin A, Duan R, Chen Y, **Panagiotou O**, Schmid CH. *Publication and Outcome Reporting Bias*. In: Handbook of Meta-Analysis. Schmid CH, Stijnen T, White IR (ed.). Chapman & Hall/CRC, 2020.

### **Impact of Scholarly Work (as of November 27, 2021)**

- According to **Google Scholar**:
  - Citations = 3,160

- *h*-index = 24; i.e., 24 of my papers have received at least as many citations)
- *m*-index = 2.4; i.e., a normalized *h*-index by the years of one's scientific production
- According to **Scopus**:
  - Citations = 2,108
  - *h*-index = 20
  - *m*-index = 1.9
- According to **Thomson ISI Web of Science**:
  - Citations = 1,959
  - *h*-index = 18
  - *m*-index = 1.8
  - Self-citation rate is 1.8%
- According to **iCite, NIH Office of Portfolio Analysis** (<https://icite.od.nih.gov>):
  - Relative citation ratio (RCR), mean = 5.18 (*i.e. my articles have received 5.18 times as many citations per year as the average NIH-funded article in its field*)
  - Relative citation ratio (RCR), weighted = 212.45 (*sum of the RCRs for my articles weighted by their influence relative to the average NIH-funded article; a highly influential set of articles has a higher weighted RCR than total number of publications*)

## SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. David S, Bergen A, Munafò M, Schuit E, Bennett D, **Panagiotou O**. Genomic analysis to guide choice of treatment for smoking cessation [Cochrane Protocol]. PROSPERO 2015 CRD42015029380 Available from: [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42015029380](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015029380)
2. **Panagiotou O**, Adam G, Trikalinos T, Ryder B, Bond D, Di M, Gazula A, Kowalski R, Smith B. Short and long term outcomes after bariatric therapies in the Medicare population. PROSPERO 2017 CRD42017065285. Available from: [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42017065285](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017065285)

## INVITED PRESENTATIONS & TALKS

### National

1. **Panagiotou OA**. Large-scale evidence and meta-research in genomic and molecular epidemiology. Biostatistics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD. September 2012.
2. **Panagiotou OA**. Biases across the continuum of animal studies translation. 3rd International Symposium on Systematic Review and Meta-Analysis of Laboratory Animal Studies, Washington, DC. November 2014.

3. **Panagiotou OA.** Effects of delaying smoking initiation on subsequent lung cancer risk and other applications of causal methods in lung cancer epidemiology. Center of Evidence-Based Medicine, Brown School of Public Health, Brown University, Providence, RI. March 2014.
4. **Panagiotou OA.** Epidemiological approaches to evaluate drug safety: applications to the NCI HPV vaccine trial. Division of Biostatistics, Office of Biostatistics & Epidemiology, Center for Biologics Evaluation & Research (CBER), US Food & Drug Administration (FDA), Silver Spring, MD. February 2015.
5. **Panagiotou OA.** Genomics in the post-GWAS era: synthesizing knowledge for disease etiology, public health, and beyond. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT. December 2015.
6. **Panagiotou OA.** Harnessing routinely collected health and other data for comparative effectiveness and safety research: Implications for the learning health care system. Department of Health Services, Policy and Practice, Brown School of Public Health, Brown University, Providence, RI. February 2016.
7. **Panagiotou OA.** Integration of evidence from multiple sources for comparative effectiveness & health policy research: where big data and evidence-based medicine intersect. Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC. March 2016.
8. **Panagiotou OA, Trikalinos TA.** Short and Long Term Outcomes after Bariatric Therapies in the Medicare Population. Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), Centers for Medicare & Medicaid Services (CMS), Baltimore, MD. August 2017.
9. **Panagiotou OA.** Evidence synthesis in the era of precision medicine: an application to pharmacotherapy for smoking cessation. Meta-Research Innovation Center at Stanford (METRICS), Stanford, CA. June 2018
10. **Panagiotou OA.** Financial incentives and the delivery of low- and high-value care. Care Transformation Collaborative Rhode Island (CTC-RI) Annual Meeting, Warwick, RI. November 2018
11. **Panagiotou OA.** Ensemble learning to estimate the effect of health insurance on utilization of low-value care. Pfizer-Brown University Knowledge Forum on Novel Analytical Methods. New York, NY. November 2019.
12. **Panagiotou OA.** Current status of the health systems in the US and Greece: a comparative discussion with Q&A. Greek Section, Foreign Service Institute, U.S. Department of State. Arlington, VA. March 2020 (*virtual presentation due to COVID-19 pandemic*)
13. **Panagiotou OA.** Replicability of treatment effects when more than one trial exists. Hebrew Senior Life-Brown University Joint Seminar Series on Clinical Trials in Aging. Providence, RI. June 2020 (*virtual presentation due to COVID-19 pandemic*).



14. **Panagiotou OA.** Replicability of evidence used for healthcare decisions. Department of Biostatistics & Data Science, University of Kansas Medical Center. Kansas City, KS. April 2021 (*virtual presentation due to COVID-19 pandemic*).
15. **Panagiotou OA.** What can we learn from large scale, routinely-collected health data? Intramural Research Program, National Library of Medicine, National Institutes of Health. Bethesda, MD. September 2021 (*virtual presentation due to COVID-19 pandemic*).

### **International**

16. **Panagiotou OA.** Epidemiology in the post-GWAS era: Leveraging millions of findings of “unknown” significance. Department of Hygiene & Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. June 2015.
17. **Panagiotou OA.** Real-World Evidence: Implications for clinical research and practice. Department of Hygiene & Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. May 2020 (*virtual presentation due to COVID-19 pandemic*)
18. **Panagiotou OA.** Predicting mortality among nursing home residents with COVID-19. COVID-19 Advisory Board for Ticino Cantone & Oncology Institute of Southern Switzerland (IOSI) / Università della Svizzera Italiana. Bellinzona, Switzerland. February 2021 (*virtual presentation due to COVID-19 pandemic*)

## **OTHER PRESENTATIONS**

### **National**

1. **Panagiotou OA.** Comparative effect sizes in randomized trials from less developed and more developed countries: meta-epidemiological assessment. 5th Annual Conference of the Consortium of Universities for Global Health, Washington, DC. May 2014
2. **Panagiotou OA.** Methodological applications for translating epidemiological evidence. NIH Earl-Stadtman Symposium in Population Sciences/Epidemiology. National Institutes of Health, Bethesda, MD. December 2014.
3. **Panagiotou OA.** Ten years of GWAS: How can we leverage their findings for causal inference? Center of Excellence in Integrative Cancer Biology and Genomics (CEICBG), National Cancer Institute, National Institutes of Health, Bethesda, MD. October 2015.
4. **Panagiotou OA.** Integration of aggregate- & individual-level information in routinely-collected health and other data: Envisioning a new role for descriptive (meta-) epidemiology. Division of Cancer Epidemiology & Genetics, National Cancer Institute,

National Institutes of Health, Rockville, MD. January 2016.

5. **Panagiotou OA.** Comparison of Hospital Readmission Rates in Medicare Advantage and Medicare Fee-for-Service. Presented in session “How Does Medicare Advantage Affect Health Care Delivery? New Evidence”. Academy Health Annual Research Meeting, Seattle, WA. June 2018.

### **International**

6. **Panagiotou OA.** Genetic associations for low-frequency genetic polymorphisms in genome-wide association studies. 1st Panhellenic Conference of the Public Health & Social Medicine Forum. Athens, Greece. November 26, 2010.

### **Conference Abstracts (selected; non-exhaustive list)**

*I herein list poster presentations where I was the lead presenter. Numerous other posters have been presented by my co-authors as lead presenters; I do not keep detailed records.*

1. **Panagiotou OA,** Gu F, Reyes-Guzman C, Landi MT, Bloch M, Caporaso NE, Wacholder S. “Causal effects of delaying smoking initiation on subsequent lung cancer risk”. American Association for Cancer Research (AACR) Annual Meeting 2014. San Diego, CA, April 2014. Poster Presentation.
2. **Panagiotou OA,** Willer CJ, Hirschhorn JN, Ioannidis JP. “The power of meta-analysis in genome-wide association studies”. The Genomics of Common Diseases 2014. Potomac, MD, September 2014. Poster Presentation.
3. **Panagiotou OA,** Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK; for the BPC3 & PRACTICAL Consortia. “Genome-wide pleiotropy scan for prostate cancer”. The Genomics of Common Diseases 2014. Potomac, MD, September 2014. Poster Presentation.
4. **Panagiotou OA,** Befano B, Gonzalez P, Porras C, Rodriguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S; for the Costa Rica HPV Vaccine Trial. Risk of miscarriage after bivalent human papillomavirus (HPV) vaccination: long-term observational follow-up of a randomized trial. Society of Epidemiological Research Annual Meeting 2015. Denver, CO, June 2015. Poster Presentation.
5. **Panagiotou OA,** Wacholder S. “Estimating additive interactions from first principles”. Society of Epidemiological Research Annual Meeting 2015. Denver, CO, June 2015. Poster Presentation.
6. **Panagiotou OA,** Caporaso NE, Landi MT, Chatterjee N; for the NCI Lung Cancer GWAS Group. C-reactive protein and lung cancer risk: a Mendelian randomization analysis.

American Association for Cancer Research (AACR) Annual Meeting 2016. New Orleans, LA, April 2016. Poster Presentation.

7. **Panagiotou OA**, Kumar A, Adhikari D, Gutman R, Keohane L, Rivera-Hernandez M, Rahman M, Gozalo P, Mor V, Trivedi AN. Impact of Including Medicare Advantage Patients on Hospitals' Readmission Rates and Financial Penalties. Academy Health Annual Research Meeting, Washington, DC. June 2019. Poster Presentation.

## GRANTS

### Current Grants

1. U01CA265750 (MPI: Trikalinos/Jalal) 09/01/21 – 08/31/26  
National Cancer Institute \$3,860,396  
Population Modeling of Bladder Cancer Detection and Control  
This project will complete the development, calibration and validation of two independent population models of bladder cancer, and will address major questions in the surveillance, treatment, prevention, and diagnosis of bladder cancer by means of comparative mathematical modeling.  
Role Co-Investigator
2. R01AG053307 (PI: Gozalo) 09/15/16 – 05/31/22  
NIA \$1,986,696  
The Impact of Accountable Care Organizations on Post Acute Care  
The proposed study will link ACO participation data, Medicare claims data and SNF, IRF and HHA assessment data across 2009-2016 to conduct a difference-in-differences person-level matched analysis that examines the impact of ACOs on PAC.  
Role: Co-Investigator
3. R01AG053307-Supplement (PI: Gozalo) 09/01/20 – 05/31/21  
NIA \$376,765  
The Impact of Accountable Care Organizations on Post Acute Care  
To provide a timely understanding of the impact on COVID-19 on PAC utilization and outcomes, and the differences associated with ACO attribution.  
Role: Co-Investigator
4. R01CA215240-01A1 (PI: Gareen) 01/17/18 – 12/31/  
National Cancer Institute \$3,038,662  
Lung Screening: Efficacy versus Effectiveness  
The goal of this project is to compare the efficacy of lung screening in community practice with that reported in the National Lung Screening Trial (NLST) with respect to the rate and type of abnormalities suspicious for lung cancer, the rate and type of significant incidental findings that are seen on lung screening and may be clinically important, but that are not

related to lung cancer, and the diagnostic testing that is done to evaluate lung and other abnormalities. We will use this information to compare the cost effectiveness of community lung screening with that estimated from the NLST and provide information that can be used to enhance the effectiveness of lung screening in the community.

Role: Co-Investigator

5. 2UG1CA189828-06-BRWN2 (Schnall, Sub PI Gatsonis) 08/01/14 – 07/31/25  
EAMRF/NCI \$1,410,414

ECOG-ACRIN NCORP Research Base - CCCR

This project involves organizing and operating a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies in Cancer Care Delivery Research (CCDR).

Role: Co-Investigator

6. 2UG1CA189828-06-BRWN1 (Schnall, Sub PI Gatsonis) 08/01/14 – 07/31/25  
EAMRF/NCI \$1,414,745

ECOG-ACRIN NCORP Research Base – CT

The Center for Statistical Sciences (CSS) at Brown University will organize and operate a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies of cancer prevention, control, and screening.

Role: Co-Investigator

7. R01AG054656 (Co-PIs: Gozalo, Grabowski) 09/15/17 – 05/31/21  
NIA \$1,707,511

Which Post-Acute Care Setting is Best for Patients' Outcomes?

The overarching goal is to examine PAC utilization and patient outcomes across different conditions and PAC settings to address important gaps in knowledge that hinder the design of current policy efforts undertaken under the Affordable Care Act (ACA) like episode-based bundling of payments and the creation of Accountable Care Organizations, aimed at improving the value of post-acute care.

Role: Co-Investigator

8. P01AG027296 (MPIs: Mor & Trivedi) 09/15/19 – 05/31/24  
NIA \$11,518,358

Alzheimer's Disease and Related Disorders Treatment and Outcomes in America: Changing Policies and Systems

This Program Project proposal seeks to understand how the high-need ADRD patients at various stages of disease progression fare under alternative payment and regulatory structures. The project proposes to study the effects of Medicare policy changes on the care and outcomes experienced by persons with ADRD who interface with home health, skilled nursing, and long-term NH Care. The four projects and three cores all focus on the effects of

national Medicare payment and quality regulation policies on the outcomes experienced by persons with ADRD.

Role: Co-Investigator

9. (PI: Wilson) 01/01/20 – 12/31/21

Department of Defense

\$1,837,157

The impact of cost sharing on medication adherence in the MHS for both non-retirees and retirees

To examine the impact of cost sharing of prescription medications in the Military Health System on medication adherence, clinical events, and clinical outcomes.

Role: Co-Investigator

### **Pending**

1. R01 (MPI: Panagiotou &Wulff-Burchfield) 09/01/21 – 08/31/26

NINR

\$3,667,300

Empowering patients with advanced cancer through optimal decision-making for personalized post-acute care planning

The overall object of this proposal is to conduct research which will support the decisions of geriatric patients with advanced cancer when choosing the optimal post-acute care settings, i.e. skilled nursing facility or home health care.

Role: Co-Principal Investigator

2. R01 (MPI: Kim/Panagiotou)

09/01/21 – 08/31/25

NIH

\$1,372,094

Effects of Medicare Advantage on Evidence-Based Screening and Early Detection of Cancer  
With breast and colorectal cancers disproportionately affecting older adults, their early detection by means of population-based screening is a proven public health strategy to reduce mortality.

Role: MPI

3. R01 (MPI: Panagiotou/Hughto)

09/01/21 – 08/31/25

NIH

\$1,999,961

Understanding multilevel determinants of cancer disparities in transgender adults

The overall objective of this proposal is to describe the burden of cancer, receipt of cancer care, multilevel (patient, clinician, community) determinants of care receipt, and related morbidity and mortality for TGD vs. cisgender people.

Role: MPI

4. R21AG075951 (Gutman/Panagiotou: MPIs)

09/01/21 –

08/31/23

NIH

\$435,504

Novel data linking approaches to estimate the risk of Alzheimer's disease and its related dementias due to cancer treatments

The overall objective of this Administrative Supplement is to develop a sustained EA resource for the cost-efficient ascertainment of long-term ADRD outcomes in cancer survivors by linking EA trials with Medicare claims data in the absence of unique identifiers.

Role: Co-Investigator

### **Completed Grants**

1. HHS290201500002I-HHSA29032009T (PI: Trikalinos) 08/19/16 – 11/30/17  
AHRQ \$222,787  
“Short and Long Term Outcomes after Bariatric Surgery in the Medicare Population”  
The purpose of this task award is to conduct a medium technology assessment on short and long term outcomes after bariatric surgery in the Medicare population  
Role: Co-Investigator
2. U54GM115677 (PIs: Panagiotou, Trikalinos) 06/01/18 – 05/31/19  
Advance-CTR/NIGMS \$49,996  
“Computational Health Services Research to Identify Use of Low-Value Care in Rhode Island”  
The goal of this project is to reduce the use of low-value care and increase the uptake of high-quality evidence-based healthcare services  
Role: Co-Principal Investigator
3. R21 AG053712-01A1 (PI: Rahman) 01/01/17 – 12/31/19  
NIA \$125,000  
“Rural-Urban Disparity in Post-Acute Care”  
This study will examine rural urban disparities in the availability, selection, utilization and outcomes of post-acute care. Lower access and quality of PAC may play a key role in rapidly widening rural-urban gap in health outcomes.  
Role: Investigator
4. 5P01 AG027296-10 (PI: Mor) 12/10/15 – 01/31/19  
NIA \$703,075  
“Changing Long Term Care in America: Policies, Markets, Strategies, and Outcomes”  
This Program Project grant proposes to study the effects of Medicare policy changes on the use of and outcomes Medicare’s post-acute care benefit and how those policies interact with long term care provider markets and states’ Medicaid policies.  
Role: Investigator
5. (PI: Trikalinos) 09/10/19 – 05/03/21  
AHRQ \$500,000  
Management of Obstructive Sleep Apnea in Medicare Population

The purpose of this single-award Task Order is to conduct 1 large technology assessment on management of Obstructive Sleep Apnea in the Medicare Population

Role: Co-Investigator

## UNIVERSITY TEACHING AND MENTORING ROLES

Role	Year	Details
<b>Instructor</b>	2012	“Genetic Epidemiology” – 20 students, faculty members, and other researchers attending the Public Health & Social Medicine Forum, Athens,
	2013	“Introduction to Genetic Association Studies” – 10 PhD student and post-doctoral researchers, Department of Hygiene & Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
	2015	“Cancer Epidemiology: Etiology, Prevention & Policy” – 10-15 pre- and post-doctoral fellows and summer students, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda,
	Spring 2019	Graduate Independent Study and Thesis Research (PHP 2980), Brown University School of Public Health
	Spring 2020	Graduate Independent Study and Thesis Research (PHP 2980), Brown University School of Public Health
<b>Invited Lectures (classroom teaching)</b>	May 2020	<i>Real-World Data &amp; Evidence</i> . Course: Hygiene & Epidemiology II (3 <sup>rd</sup> year medical students). University of Ioannina School of Medicine,
	November 2020	<i>An Introduction to Evidence Synthesis</i> . HIDS 504: Evidence-based data analysis in population health.
	November 2021	Master’s in Health Informatics and Data Science. Georgetown University, Washington, DC
<b>Grand Rounds</b>	2017	Dermatology Research Meeting, Department of Dermatology, Brown University Alpert Medical
<b>Post-doctoral Mentor</b>	2020 - 2021	<i>Jacqueline Ellison, PhD</i> – Post-doctoral Fellow, Center for Gerontology and Healthcare Research, Brown University School of Public Health
<b>Thesis Advisor</b>	2019 - 2020	<i>Kirsten Voorhies</i> – ScM Thesis, Department of Biostatistics, Brown University School of Public Health
	2020 - 2021	<i>Joyce Pak</i> – MPH Thesis, Brown University School of Public Health <i>Soryan Kumar</i> – Honors Thesis in Applied



<b>Thesis Reader</b>	2017 - 2018	<i>Jiachen Zhang</i> – ScM Thesis, Department of Biostatistics, Brown University School of Public Health
	2019 - 2020	<i>Emma Creegan</i> – MPH Thesis, Brown University School of Public Health
<b>Student Mentor</b>	2017	<i>Shaun Forbes</i> – PhD Program, Department of Health Services, Policy & Practice, Brown University School of Public Health
	2020	<i>Emily Nomura</i> – Summer research student supported by Brown University’s Karen T. Romer Undergraduate Teaching and Research Award

---